Chronic multifocal osteomyelitis

Syncromune Appoints Dr. Stephen P. Dale as Chief Medical Officer

3 weeks ago talkbio0Tagged Appointments, Biological Factors, Chronic multifocal osteomyelitis, Neoplasms, Stephen P. Dale, SYNC-T, Syncromune

Syncromune; Stephen P. Dale; CMO; appointment; oncology; SYNC-T; biopharmaceutical

Genelux Corporation Appoints Jason Litten, M.D., as Chief Medical Officer to Advance Olvi-Vec Development

3 weeks ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Genelux Corporation, immuno-oncology, Jason Litten

Genelux Corporation; Jason Litten; Chief Medical Officer; CMO; Olvi-Vec; immuno-oncology; clinical trials

Whitehawk Therapeutics Appoints Margaret Dugan as Chief Medical Officer

2 months ago talkbio0Tagged Chief Medical Officer, Chronic multifocal osteomyelitis, Clinical Trials, Dracen Pharmaceuticals, Drug Development, Margaret Dugan, Neoplasms, Novartis, Schrödinger, therapeutic autologous dendritic cells, Whitehawk Therapeutics

Whitehawk Therapeutics; Margaret Dugan; Chief Medical Officer; CMO; oncology; ADC; drug development; clinical trials; Novartis; Dracen Pharmaceuticals; Schrödinger

Editas Medicine Undergoes Major Restructuring, Laying Off 65% of Staff Including CMO Amid Failed Search for RENI-CEL Partner

1 year ago talkbio0Tagged Anemia, Sickle Cell, Chronic multifocal osteomyelitis, Editas Medicine, Gene Modification, RENI-CEL, restructuring, Thalassemia

Editas Medicine, layoffs, gene editing, biotech, RENI-CEL, sickle cell disease, thalassaemia, CMO, workforce reduction, restructuring.